Histology of Luminal Breast Cancer

被引:21
|
作者
Erber, Ramona [1 ]
Hartmann, Arndt [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Comprehens Canc Ctr Erlangen EMN, Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany
关键词
Luminal A; Luminal B; Breast cancer; Estrogen receptor; Histological subtypes; INVASIVE CRIBRIFORM CARCINOMA; LOBULAR CARCINOMA; MICROPAPILLARY CARCINOMA; SEBACEOUS CARCINOMA; DUCTAL CARCINOMA; IN-SITU; CLINICOPATHOLOGICAL FEATURES; TUBULOLOBULAR CARCINOMA; MUCINOUS CARCINOMA; APOCRINE CARCINOMA;
D O I
10.1159/000509025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:Invasive breast cancer (IBC) can be categorized into prognostic and predictive molecular subtypes (including luminal breast cancer) using gene expression profiling. Luminal IBC comprises a variety of histological subtypes with varying clinical and pathological features.Summary:IBC of no special subtype is the most common histological subtype in general and likewise within luminal IBC. Classical invasive lobular breast cancer, typically clustering into luminal subgroup, is characterized by discohesive growth and loss of E-cadherin expression. Infrequent, morphologically distinct luminal IBC subtypes are tubular, invasive cribriform, mucinous, and invasive micropapillary carcinomas. Breast carcinoma with apocrine differentiation, with characteristic expression of androgen receptor (AR), often clusters into the luminal AR category. Rarely, neuroendocrine neoplasms of the breast can be seen. IBC of the male breast usually matches with the luminal subtype.Key Messages:Independently from histological subtypes, invasive breast cancer (IBC) can be divided into molecular subtypes based on mRNA gene expression levels. Using this molecular subtyping, risk scores based on gene expression profiling (established for hormone receptor-positive, HER2-negative IBC), grading, and Ki-67 index, prognosis of patients with luminal breast cancer and response to chemotherapy can be predicted. In routine diagnostics, the expression of estrogen receptor (ER) and progesterone receptor (PR), HER2 status, and the proliferation rate (Ki-67) are used to determine a surrogate (molecular-like) subtype. Within luminal(-like) IBC, no special subtype and invasive lobular breast carcinoma are the most common histological subtypes. Other rare histological subtypes (e.g., tubular carcinoma) should be recognized due to their distinct clinical and pathological features.
引用
收藏
页码:327 / 336
页数:10
相关论文
共 50 条
  • [1] Translational breast cancer research in luminal breast cancer
    M Dowsett
    Breast Cancer Research, 13
  • [2] Translational breast cancer research in luminal breast cancer
    Dowsett, M.
    BREAST CANCER RESEARCH, 2011, 13
  • [3] Luminal Metastatic Breast Cancer
    Huober, Jens
    Bartsch, Rupert
    Marme, Frederik
    Pagani, Olivia
    Thomssen, Christoph
    BREAST CARE, 2019, 14 (02) : 99 - 101
  • [4] LDHA is differential expressed in luminal A and luminal B breast cancer
    Vieira, F. Q.
    Cardoso, A. R.
    Gigliano, D.
    Carneiro, I.
    Henrique, R.
    Jeronimo, C.
    Silva, R. A.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2021, 31
  • [5] Molecular heterogeneity of luminal breast cancer
    Loi, S.
    BREAST CANCER RESEARCH, 2011, 13
  • [6] Molecular heterogeneity of luminal breast cancer
    S Loi
    Breast Cancer Research, 13
  • [7] Genomic Profiling in Luminal Breast Cancer
    Gluz, Oleg
    Hofmann, Daniel
    Wuerstlein, Rachel
    Liedtke, Cornelia
    Nitz, Ulrike
    Harbeck, Nadia
    BREAST CARE, 2013, 8 (06) : 414 - 422
  • [8] Advances in the treatment of luminal breast cancer
    Howell, Sacha J.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2013, 25 (01) : 49 - 54
  • [9] Effect of Chemotherapy for Luminal A Breast Cancer
    Uchida, Naotaka
    Suda, Takako
    Ishiguro, Kiyosuke
    YONAGO ACTA MEDICA, 2013, 56 (02) : 51 - 56
  • [10] Genomic Signatures in Luminal Breast Cancer
    Puppe, Julian
    Seifert, Tabea
    Eichler, Christian
    Pilch, Henryk
    Mallmann, Peter
    Malter, Wolfram
    BREAST CARE, 2020, 15 (04) : 355 - 365